Arrowhead Pharma (ARWR) 5.85 $ARWR
Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B Candidate ARC-521
BusinessWire - Thu Jun 09, 6:30AM CDT
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it initiated a Phase 1/2 study of ARC-521, the company's second RNAi-based investigational medicine for the treatment of chronic hepatitis B virus (HBV) infection. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single doses of ARC-521 in healthy volunteers and the safety, tolerability, and antiviral activity of single and multiple doses of ARC-521 in patients with chronic HBV. This study may have multiple readouts, including single dose safety data, single dose antiviral activity data, and multiple dose safety and antiviral activity data.
ARWR: 5.85 (-0.14)
Arrowhead Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Fri Jun 03, 6:30AM CDT
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that chief operating officer and head of R&D Bruce Given, M.D., will present at the Jefferies 2016 Healthcare Conference on June 10, 2016 at 10:30 a.m. EDT. Investors may access live and archived versions of the audio webcast of this presentation on the Events and Presentations page under the Investors section of the Arrowhead website.
ARWR: 5.85 (-0.14)
How Well are These Healthcare Stocks Performing? - Radius Health, Cerus, Arrowhead Pharma, and Five Prime Therapeutics
PR Newswire - Thu May 26, 7:50AM CDT
Despite the volatility that continues to envelop the Biotech industry, investors see value in this space. Today's pre-market research on ActiveWallSt.com directs the investor community's focus on the following Healthcare equities: Radius Health Inc. (NASDAQ: RDUS), Cerus Corp. (NASDAQ: CERS), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Five Prime Therapeutics Inc. (NASDAQ: FPRX). Register with us today for these stock technical briefings at:
CERS: 6.09 (+0.12), RDUS: 36.64 (-0.05), ARWR: 5.85 (-0.14), FPRX: 42.87 (+0.69)
Arrowhead Research Shares Up 20.5% Since SmarTrend's Buy Recommendation (ARWR)
Comtex SmarTrend(R) - Mon May 16, 1:43PM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 3 months, Arrowhead Research has returned 20.51% as of today's recent price of $5.17.
ARWR: 5.85 (-0.14)
Arrowhead Reports Fiscal 2016 Second Quarter Results
BusinessWire - Tue May 10, 3:01PM CDT
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 second quarter ended March 31, 2016. The company is hosting a conference call at 4:30 p.m. EDT to discuss results.
ARWR: 5.85 (-0.14)
Uptrend Call Working As Arrowhead Research Stock Rises 33.8% (ARWR)
Comtex SmarTrend(R) - Mon May 09, 1:38PM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 2 months, Arrowhead Research has returned 33.80% as of today's recent price of $5.74.
ARWR: 5.85 (-0.14)
Arrowhead Pharmaceuticals' Preclinical Candidate ARC-LPA Achieves 98% Knockdown and Long Duration of Effect after Subcutaneous Administration
BusinessWire - Fri May 06, 11:00AM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented a poster on ARC-LPA, its preclinical development program targeting lipoprotein (a), or Lp(a), for the treatment of cardiovascular disease at the Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease (ATVB|PVD) 2016 Scientific Sessions in Nashville. ARC-LPA is the first RNAi therapeutic program to use Arrowhead's new delivery vehicles designed for subcutaneous (SQ) administration.
ARWR: 5.85 (-0.14)
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Second Quarter Results
BusinessWire - Tue May 03, 3:01PM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Tuesday, May 10, 2016, at 4:30 p.m. EDT to discuss its financial results for the fiscal 2016 second quarter ended March 31, 2016. Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and enter Conference ID 5054757.
ARWR: 5.85 (-0.14)
34.3% Return Seen to Date on SmarTrend Arrowhead Research Call (ARWR)
Comtex SmarTrend(R) - Fri Apr 29, 1:18PM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 2 months, Arrowhead Research has returned 34.27% as of today's recent price of $5.76.
ARWR: 5.85 (-0.14)
Arrowhead Pharmaceuticals to Present at Upcoming May Conferences
BusinessWire - Fri Apr 29, 6:30AM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcoming events.
ARWR: 5.85 (-0.14)
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521
BusinessWire - Thu Apr 28, 6:30AM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), recently filed a regulatory submission in New Zealand to begin a Phase 1/2 clinical trial of ARC-521, its RNAi-based therapeutic candidate for the treatment of chronic hepatitis B virus (HBV) infection. Pending approval, Arrowhead intends to proceed with ARC521-1001, a first-in-human study to assess single and multiple-doses of ARC-521 in healthy volunteers and HBV patients.
ARWR: 5.85 (-0.14)
Can Arrowhead Do For Hep B What Gilead Sciences Did For Hep C?
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 25, 5:01PM CDT
SOURCE: ARROWHEAD PHARMA Arrowhead Pharmaceuticals recently offered up insight into potential efficacy for its clinical-stage hepatitis B drug ARC-520 that suggest it may offer the best chance yet at a functional cure for hepatitis B, a common...
GILD: 84.45 (-1.32), ARWR: 5.85 (-0.14), BMY: 72.65 (-0.08)
Arrowhead Research Has Returned 42.9% Since SmarTrend Recommendation (ARWR)
Comtex SmarTrend(R) - Fri Apr 22, 12:23AM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 2 months, Arrowhead Research has returned 42.89% as of today's recent price of $6.13.
ARWR: 5.85 (-0.14)
Arrowhead Research Up 39.4% Since SmarTrend Uptrend Call (ARWR)
Comtex SmarTrend(R) - Thu Apr 14, 12:53PM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 1 month, Arrowhead Research has returned 39.39% as of today's recent price of $5.98.
ARWR: 5.85 (-0.14)
4 Hot Trending Small Cap Stocks That You Haven't Heard About
ACCESSWIRE - Thu Apr 14, 8:57AM CDT
NEW YORK, NY / ACCESSWIRE / April 14, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. SPWH, CONN, PEG and ARWR are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
ARWR: 5.85 (-0.14), PEG: 44.36 (-0.26), CONN: 8.17 (-0.32), SPWH: 8.25 (-0.09)
Better Buy: Inovio Pharmaceuticals or Arrowhead Research Corp.?
Keith Speights, The Motley Fool - Motley Fool - Thu Apr 14, 8:21AM CDT
Image source: Inovio Pharmaceuticals. Biotech investors have been a sad bunch lately. Politicians slamming high drug prices combined with general market uncertainties have clobbered many biotech stocks over the last several months. Arrowhead...
INO: 10.62 (-0.39), GILD: 84.45 (-1.32), ARWR: 5.85 (-0.14)
What Caused Arrowhead Pharmaceuticals to Skyrocket 13% Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 13, 3:58PM CDT
Image source: Arrowhead Pharmaceuticals. What: After reporting data from an early-stage study of its ARC-520 in hepatitis B patients, shares of Arrowhead Pharmaceuticals shot 12.9% higher today. So what: The clinical-stage researcher of...
ARWR: 5.85 (-0.14), BMY: 72.65 (-0.08)
Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data at The International Liver Congress(TM) 2016
BusinessWire - Wed Apr 13, 6:30AM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that three presentations are being made on ARC-520, its investigational medicine for the treatment of chronic hepatitis B infection, at The International Liver Congress(TM) 2016 (ILC 2016), in Barcelona, Spain, April 13-17, 2016.
ARWR: 5.85 (-0.14)
Arrowhead Research Changes Name to Arrowhead Pharmaceuticals
BusinessWire - Wed Apr 06, 3:01PM CDT
Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it has changed its corporate name to Arrowhead Pharmaceuticals, Inc. The company's common stock will continue to trade on the NASDAQ Global Select Market under the existing stock ticker symbol, ARWR. These shares have been assigned a new CUSIP number of 04280A100. Holders of stock certificates with the prior corporate name, need not take any action.
ARWR: 5.85 (-0.14)
Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B Candidate ARC-521
BusinessWire - Thu Jun 09, 6:30AM CDT
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it initiated a Phase 1/2 study of ARC-521, the company's second RNAi-based investigational medicine for the treatment of chronic hepatitis B virus (HBV) infection. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single doses of ARC-521 in healthy volunteers and the safety, tolerability, and antiviral activity of single and multiple doses of ARC-521 in patients with chronic HBV. This study may have multiple readouts, including single dose safety data, single dose antiviral activity data, and multiple dose safety and antiviral activity data.
ARWR: 5.85 (-0.14)
Arrowhead Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Fri Jun 03, 6:30AM CDT
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that chief operating officer and head of R&D Bruce Given, M.D., will present at the Jefferies 2016 Healthcare Conference on June 10, 2016 at 10:30 a.m. EDT. Investors may access live and archived versions of the audio webcast of this presentation on the Events and Presentations page under the Investors section of the Arrowhead website.
ARWR: 5.85 (-0.14)
How Well are These Healthcare Stocks Performing? - Radius Health, Cerus, Arrowhead Pharma, and Five Prime Therapeutics
PR Newswire - Thu May 26, 7:50AM CDT
Despite the volatility that continues to envelop the Biotech industry, investors see value in this space. Today's pre-market research on ActiveWallSt.com directs the investor community's focus on the following Healthcare equities: Radius Health Inc. (NASDAQ: RDUS), Cerus Corp. (NASDAQ: CERS), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Five Prime Therapeutics Inc. (NASDAQ: FPRX). Register with us today for these stock technical briefings at:
CERS: 6.09 (+0.12), RDUS: 36.64 (-0.05), ARWR: 5.85 (-0.14), FPRX: 42.87 (+0.69)
Arrowhead Research Shares Up 20.5% Since SmarTrend's Buy Recommendation (ARWR)
Comtex SmarTrend(R) - Mon May 16, 1:43PM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 3 months, Arrowhead Research has returned 20.51% as of today's recent price of $5.17.
ARWR: 5.85 (-0.14)
Arrowhead Reports Fiscal 2016 Second Quarter Results
BusinessWire - Tue May 10, 3:01PM CDT
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 second quarter ended March 31, 2016. The company is hosting a conference call at 4:30 p.m. EDT to discuss results.
ARWR: 5.85 (-0.14)
Uptrend Call Working As Arrowhead Research Stock Rises 33.8% (ARWR)
Comtex SmarTrend(R) - Mon May 09, 1:38PM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 2 months, Arrowhead Research has returned 33.80% as of today's recent price of $5.74.
ARWR: 5.85 (-0.14)
Arrowhead Pharmaceuticals' Preclinical Candidate ARC-LPA Achieves 98% Knockdown and Long Duration of Effect after Subcutaneous Administration
BusinessWire - Fri May 06, 11:00AM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented a poster on ARC-LPA, its preclinical development program targeting lipoprotein (a), or Lp(a), for the treatment of cardiovascular disease at the Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease (ATVB|PVD) 2016 Scientific Sessions in Nashville. ARC-LPA is the first RNAi therapeutic program to use Arrowhead's new delivery vehicles designed for subcutaneous (SQ) administration.
ARWR: 5.85 (-0.14)
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Second Quarter Results
BusinessWire - Tue May 03, 3:01PM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Tuesday, May 10, 2016, at 4:30 p.m. EDT to discuss its financial results for the fiscal 2016 second quarter ended March 31, 2016. Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and enter Conference ID 5054757.
ARWR: 5.85 (-0.14)
34.3% Return Seen to Date on SmarTrend Arrowhead Research Call (ARWR)
Comtex SmarTrend(R) - Fri Apr 29, 1:18PM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 2 months, Arrowhead Research has returned 34.27% as of today's recent price of $5.76.
ARWR: 5.85 (-0.14)
Arrowhead Pharmaceuticals to Present at Upcoming May Conferences
BusinessWire - Fri Apr 29, 6:30AM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcoming events.
ARWR: 5.85 (-0.14)
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521
BusinessWire - Thu Apr 28, 6:30AM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), recently filed a regulatory submission in New Zealand to begin a Phase 1/2 clinical trial of ARC-521, its RNAi-based therapeutic candidate for the treatment of chronic hepatitis B virus (HBV) infection. Pending approval, Arrowhead intends to proceed with ARC521-1001, a first-in-human study to assess single and multiple-doses of ARC-521 in healthy volunteers and HBV patients.
ARWR: 5.85 (-0.14)
Can Arrowhead Do For Hep B What Gilead Sciences Did For Hep C?
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 25, 5:01PM CDT
SOURCE: ARROWHEAD PHARMA Arrowhead Pharmaceuticals recently offered up insight into potential efficacy for its clinical-stage hepatitis B drug ARC-520 that suggest it may offer the best chance yet at a functional cure for hepatitis B, a common...
GILD: 84.45 (-1.32), ARWR: 5.85 (-0.14), BMY: 72.65 (-0.08)
Arrowhead Research Has Returned 42.9% Since SmarTrend Recommendation (ARWR)
Comtex SmarTrend(R) - Fri Apr 22, 12:23AM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 2 months, Arrowhead Research has returned 42.89% as of today's recent price of $6.13.
ARWR: 5.85 (-0.14)
Arrowhead Research Up 39.4% Since SmarTrend Uptrend Call (ARWR)
Comtex SmarTrend(R) - Thu Apr 14, 12:53PM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 1 month, Arrowhead Research has returned 39.39% as of today's recent price of $5.98.
ARWR: 5.85 (-0.14)
4 Hot Trending Small Cap Stocks That You Haven't Heard About
ACCESSWIRE - Thu Apr 14, 8:57AM CDT
NEW YORK, NY / ACCESSWIRE / April 14, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. SPWH, CONN, PEG and ARWR are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
ARWR: 5.85 (-0.14), PEG: 44.36 (-0.26), CONN: 8.17 (-0.32), SPWH: 8.25 (-0.09)
Better Buy: Inovio Pharmaceuticals or Arrowhead Research Corp.?
Keith Speights, The Motley Fool - Motley Fool - Thu Apr 14, 8:21AM CDT
Image source: Inovio Pharmaceuticals. Biotech investors have been a sad bunch lately. Politicians slamming high drug prices combined with general market uncertainties have clobbered many biotech stocks over the last several months. Arrowhead...
INO: 10.62 (-0.39), GILD: 84.45 (-1.32), ARWR: 5.85 (-0.14)
What Caused Arrowhead Pharmaceuticals to Skyrocket 13% Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 13, 3:58PM CDT
Image source: Arrowhead Pharmaceuticals. What: After reporting data from an early-stage study of its ARC-520 in hepatitis B patients, shares of Arrowhead Pharmaceuticals shot 12.9% higher today. So what: The clinical-stage researcher of...
ARWR: 5.85 (-0.14), BMY: 72.65 (-0.08)
Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data at The International Liver Congress(TM) 2016
BusinessWire - Wed Apr 13, 6:30AM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that three presentations are being made on ARC-520, its investigational medicine for the treatment of chronic hepatitis B infection, at The International Liver Congress(TM) 2016 (ILC 2016), in Barcelona, Spain, April 13-17, 2016.
ARWR: 5.85 (-0.14)
Arrowhead Research Changes Name to Arrowhead Pharmaceuticals
BusinessWire - Wed Apr 06, 3:01PM CDT
Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it has changed its corporate name to Arrowhead Pharmaceuticals, Inc. The company's common stock will continue to trade on the NASDAQ Global Select Market under the existing stock ticker symbol, ARWR. These shares have been assigned a new CUSIP number of 04280A100. Holders of stock certificates with the prior corporate name, need not take any action.
ARWR: 5.85 (-0.14)
